Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AtheroGenics To Lay Off Half Its Workforce On Heels Of ARISE Failure, AstraZeneca Pullout

This article was originally published in The Pink Sheet Daily

Executive Summary

Initiative will free up funds needed to file NDA on AGI-1067 without former partner AstraZeneca.
Advertisement

Related Content

Credit Woes Hit Pharma
AtheroGenics Completes Enrollment Of Phase III AGI-1067 Diabetes Study
AtheroGenics Completes Enrollment Of Phase III AGI-1067 Diabetes Study
Atherogenics Switches Focus For AGI-1067 To Glycemic Control In Diabetes
Atherogenics Switches Focus For AGI-1067 To Glycemic Control In Diabetes
AstraZeneca Accelerates Biologics Strategy With Acquisition Of MedImmune
AstraZeneca Accelerates Biologics Strategy With Acquisition Of MedImmune
Outlook For AstraZeneca/AtheroGenics’ Candidate May Sink On ARISE Trial Results
AtheroGenics' AGI-1067 Pivotal Data Expected In Late Q1

Topics

Advertisement
UsernamePublicRestriction

Register

PS066096

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel